Kodiak Sciences Inc Common Stock (KOD) Stock Price
KODStock
$39.46+264.90%52W
Market Cap$2.48B
P/E—
PEG Ratio—
Div yield—
Beta2.22
KOD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)40.18%
Price vs S&P 500 (4W)-10.67%
VGM Score62.36
KOD Earnings Surprise History
Q2 25-1.03est. -1.05
Q3 25-1.16est. -1.04
Q4 25-1.04est. -1.05
Q1 26-0.94est. -1.01
Q2 26-1.05est. -0.96
KOD Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.09
4.09
4.10
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KODKodiak Sciences Inc Common Stock | — | — | B | $39.46 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Kodiak Sciences Inc Common Stock
Kodiak Sciences is a biopharmaceutical company developing novel therapeutics for high-prevalence retinal diseases, with a focus on wet age-related macular degeneration. The company's clinical-stage pipeline includes an antibody biopolymer conjugate for previously untreated wet AMD patients, along with additional candidates such as Tarcocimab tedromer, KSI-501, and KSI-101. These programs target significant unmet needs in retinal disease treatment.